BioAegis Therapeutics has entered into an exclusive option agreement with Brigham and Women’s Hospital granting BioAegis a worldwide license for therapeutic and diagnostic use of Brigham’s technology for human and animal applications. The technology is based on the research of founding scientist Dr. Thomas Stossel, director, Translational Medicine at Brigham and Women’s Hospital, and collaborators at Massachusetts General Hospital, University of Pennsylvania, Beth Israel Deaconess Medical Center...